The Challenges of Treating Metastatic Melanoma With BRAF Inhibitor Monotherapy
Adil Daud, MD, clinical professor, medicine, dermatology, University of California, San Francisco, discusses the challenges of treating patients with metastatic melanoma with BRAF inhibitor monotherapy.
Adil Daud, MD, clinical professor, medicine, dermatology, University of California, San Francisco, discusses the challenges of treating patients with metastatic melanoma with BRAF inhibitor monotherapy.
At the Society for Melanoma Research 2013 Congress, Daud presented an overall survival update for BRF113220 part C, a phase II three-arm randomized study of dabrafenib alone versus combination of dabrafenib and trametinib in patients with BRAF V600 mutation-positive metastatic melanoma.
Read about the treatment of melanoma withcombinations and immunotherapies
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
Oncologists Discuss a Second-Generation BTK for Relapsed/Refractory CLL
December 18th 2024During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed chronic lymphocytic leukemia after receiving venetoclax and obinutuzumab.
Read More
